Merck & Co., Inc. (MRK)
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) Bank of America Global Healthcare Conference September 18, 2024 6:40 AM ET Company Participants Joseph Romanelli - President, Human Health International Peter Dannenbaum - Head of Investor Relations Conference Call Participants Chen Yang - Bank of America Chen Yang Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations.
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with asbestos.
Where Will Merck Stock Be in 5 Years?
Its blockbuster Keytruda cancer drug is scheduled to lose patent protection by the end of this decade. The company is betting on an extensive candidate pipeline and new indications to drive long-term growth.
Merck Appears Ready To Return To June Highs (Technical Analysis)
Merck's 15% decline in July is presenting investors with an intermediate to long-term buying opportunity. Long-term trend lines and Bollinger Bands indicate strong support at $110. We expect Merck to return to the July high of $133. Sentiment indicators show "too many" investors expect lower prices for Merck, which is a positive signal for higher prices.
Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know
In the most recent trading session, Merck (MRK) closed at $115.86, indicating a +0.53% shift from the previous trading day.
Here's Why Merck (MRK) Gained But Lagged the Market Today
Merck (MRK) closed at $115.25 in the latest trading session, marking a +0.47% move from the prior day.
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck's blockbuster Keytruda.
Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial
Summit Therapeutics said its Ivonescimab treatment reduced the risk of disease progression or death by 49% compared with the market leader.
Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 2:35 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President of Merck Research Laboratories Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Good afternoon, everybody. Thanks for joining us.
